Immunotech Laboratories, Inc. announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd. (Uldic), located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company’s HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa.
With the establishment of an African operation, Immunotech hopes to fulfill the Company’s vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus. In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company’s new agreement with Uldic.
ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use today. IPF has not shown itself to be subject to viral resistance, and it is cost effective.
The Company says that the immune system has components that bind and present antigens to cells that are capable of initiating a response to those antigens. CD1d CD 56 molecules are a family of highly conserved antigen-presenting proteins that bind lipids and glycolipids, resulting in activation of natural killer T-cells (NKT cells) to elicit protective immunity against the immunogen.
Immunotech has isolated IPF which is the most extensively studied CD 56 ligand to date. The compounds has their ability to stimulate human NKT-cell lines, secretion of key cytokines such as IFN- IL 2 and IL-12, and activate autologous dendritic cells, as well as binding to CD1d and the invariant T-cell receptor. A lead compound, IPF, emerged from these studies and this protein exhibits a stronger adjuvant effect in various HIV vaccine platforms in mice. IPF also provides a protective adjuvant effect with a candidate HIV and
While the majority of the Company’s studies have focused on the potential of the IPF as a vaccine adjuvant, it is foreseeable that the compounds could also be used as a potential immuno-therapeutic to treat infectious diseases.